TWI429405B - 用於靜脈營養療法的小兒胺基酸溶液 - Google Patents
用於靜脈營養療法的小兒胺基酸溶液 Download PDFInfo
- Publication number
- TWI429405B TWI429405B TW096108010A TW96108010A TWI429405B TW I429405 B TWI429405 B TW I429405B TW 096108010 A TW096108010 A TW 096108010A TW 96108010 A TW96108010 A TW 96108010A TW I429405 B TWI429405 B TW I429405B
- Authority
- TW
- Taiwan
- Prior art keywords
- amino acid
- acid solution
- grams
- tyrosine
- per
- Prior art date
Links
- 150000001413 amino acids Chemical class 0.000 title claims description 110
- 235000016236 parenteral nutrition Nutrition 0.000 title 1
- 235000001014 amino acid Nutrition 0.000 claims description 93
- 239000000243 solution Substances 0.000 claims description 57
- 238000001990 intravenous administration Methods 0.000 claims description 39
- 235000016709 nutrition Nutrition 0.000 claims description 34
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 30
- 230000035764 nutrition Effects 0.000 claims description 28
- 239000004220 glutamic acid Substances 0.000 claims description 27
- 238000002560 therapeutic procedure Methods 0.000 claims description 25
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 24
- 235000013922 glutamic acid Nutrition 0.000 claims description 24
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 24
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 16
- 235000018417 cysteine Nutrition 0.000 claims description 15
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 15
- 235000018102 proteins Nutrition 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 229960003080 taurine Drugs 0.000 claims description 15
- 230000001954 sterilising effect Effects 0.000 claims description 14
- 238000004659 sterilization and disinfection Methods 0.000 claims description 14
- 108010038807 Oligopeptides Proteins 0.000 claims description 13
- 102000015636 Oligopeptides Human genes 0.000 claims description 13
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 12
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 7
- 229930182817 methionine Natural products 0.000 claims description 7
- 239000003792 electrolyte Substances 0.000 claims description 5
- 235000013619 trace mineral Nutrition 0.000 claims description 5
- 239000011573 trace mineral Substances 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- -1 glycidyl tyrosine Chemical compound 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 208000020455 intestinal malformation Diseases 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- DRONMCPAZUCCKN-DFWYDOINSA-N (2S)-2-aminopentanedioic acid propan-1-amine Chemical compound CCCN.OC(=O)[C@@H](N)CCC(O)=O DRONMCPAZUCCKN-DFWYDOINSA-N 0.000 claims 1
- YPLBFIUHQOIKAO-GDVGLLTNSA-N (2s)-2-(oxiran-2-ylmethylamino)pentanedioic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NCC1CO1 YPLBFIUHQOIKAO-GDVGLLTNSA-N 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- 239000003978 infusion fluid Substances 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 23
- 235000002374 tyrosine Nutrition 0.000 description 18
- 230000002028 premature Effects 0.000 description 11
- 230000037396 body weight Effects 0.000 description 10
- 239000002243 precursor Substances 0.000 description 9
- 108010016626 Dipeptides Proteins 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 238000010276 construction Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000007857 degradation product Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003797 essential amino acid Substances 0.000 description 4
- 235000020776 essential amino acid Nutrition 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- 206010036590 Premature baby Diseases 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000002960 lipid emulsion Substances 0.000 description 2
- 150000004667 medium chain fatty acids Chemical class 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 238000011903 nutritional therapy Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- QOTVYVAWKGLTFE-JTQLQIEISA-N C(C)(=O)NN[C@@H](CC1=CC=C(C=C1)O)C(=O)O Chemical compound C(C)(=O)NN[C@@H](CC1=CC=C(C=C1)O)C(=O)O QOTVYVAWKGLTFE-JTQLQIEISA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- 102100026278 Cysteine sulfinic acid decarboxylase Human genes 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 206010017877 Gastrointestinal fistula Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 description 1
- 102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 1
- 229940099500 cystamine Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000008571 general function Effects 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 230000036433 growing body Effects 0.000 description 1
- MVYQJCPZZBFMLF-UHFFFAOYSA-N hydron;propan-1-amine;bromide Chemical compound [Br-].CCC[NH3+] MVYQJCPZZBFMLF-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 108010058198 sulfoalanine decarboxylase Proteins 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Pediatric Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006018293A DE102006018293A1 (de) | 2006-04-20 | 2006-04-20 | Pädiatrische Aminosäurelösung zur parenteralen Ernäherung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200740380A TW200740380A (en) | 2007-11-01 |
| TWI429405B true TWI429405B (zh) | 2014-03-11 |
Family
ID=38006821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW096108010A TWI429405B (zh) | 2006-04-20 | 2007-03-08 | 用於靜脈營養療法的小兒胺基酸溶液 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8377876B2 (enExample) |
| EP (1) | EP2007348B1 (enExample) |
| JP (1) | JP2009534323A (enExample) |
| KR (1) | KR20090010050A (enExample) |
| CN (2) | CN101420933A (enExample) |
| AR (1) | AR060555A1 (enExample) |
| AU (1) | AU2007241469B2 (enExample) |
| BR (1) | BRPI0710298A2 (enExample) |
| CA (1) | CA2647087A1 (enExample) |
| DE (1) | DE102006018293A1 (enExample) |
| EA (1) | EA015709B1 (enExample) |
| MX (1) | MX2008013540A (enExample) |
| TW (1) | TWI429405B (enExample) |
| WO (1) | WO2007121807A1 (enExample) |
| ZA (1) | ZA200807860B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102065698A (zh) | 2008-06-19 | 2011-05-18 | 荷兰联合利华有限公司 | 具有铁和锌的含脂肪食用乳液 |
| AU2009268742C1 (en) | 2008-07-07 | 2013-11-28 | Pentec Health, Inc. | Nutritive compositions and methods of using same |
| JP2011121889A (ja) * | 2009-12-09 | 2011-06-23 | En Otsuka Pharmaceutical Co Ltd | 炎症性腸疾患用アミノ酸組成物 |
| CA2786375A1 (en) * | 2010-01-04 | 2011-07-07 | Pentec Health, Inc. | Nutritive compositions and methods of using same |
| JP2011144116A (ja) * | 2010-01-12 | 2011-07-28 | En Otsuka Pharmaceutical Co Ltd | 炎症性腸疾患用添加剤 |
| US20110208153A1 (en) * | 2010-02-24 | 2011-08-25 | John Alvey | Formulations and methods for nutrient delivery |
| JP6000253B2 (ja) | 2010-09-24 | 2016-09-28 | ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド | 胃腸機能を改善するための材料および方法 |
| EP2489408A1 (de) * | 2011-01-13 | 2012-08-22 | Michael Tchirikov | Aminosäurezusammensetzung und deren Verwendung zur Behandlung von fetaler Wachstumsrestriktion (IUGR) und zur parenteralen Ernährung von extrem Frühgeborenen |
| CN104039174B (zh) * | 2012-01-09 | 2016-11-16 | N·V·努特里奇亚 | 用于早产婴儿的富含谷氨酰胺的营养组合物 |
| MX368543B (es) * | 2012-02-08 | 2019-10-07 | Univ Florida | Composiciones para tratar diarrea inducida por rotavirus. |
| BR112015016465B1 (pt) * | 2013-01-09 | 2020-11-10 | N.V. Nutricia | uso de glutamina ou de uma composição; método não-medicinal para melhora posterior da função cognitiva em um bebê muito prematuro nascido pequeno para a idade gestacional; e método não-medicinal para melhora posterior do q.i em um bebê muito prematuro nascido pequeno para a idade gestacional |
| WO2014164736A1 (en) | 2013-03-11 | 2014-10-09 | University Of Florida Research Foundation, Incorporated | Materials and methods for improving lung function and for prevention and/or treatment of radiation-induced lung complications |
| CN103404934B (zh) * | 2013-08-24 | 2015-07-01 | 江苏阜丰生物科技有限公司 | 一种含谷氨酰胺的解酒固体饮料及其制备方法 |
| WO2015178762A1 (en) * | 2014-05-19 | 2015-11-26 | N.V. Nutricia | Enteral formulations for preterm infants comprising optimised phenylalanine intake levels |
| WO2015178761A1 (en) | 2014-05-19 | 2015-11-26 | N.V. Nutricia | Formulas comprising optimised amino acid profiles |
| JOP20190276A1 (ar) * | 2017-05-31 | 2019-11-27 | Napo Pharmaceuticals Inc | طرق وتركيبات لعلاج إسهال الحمض الصفراوي، والإسهال المرتبط باستئصال الأمعاء الدقيقة أو إزالة المرارة، ومتلازمة الأمعاء القصيرة |
| CN107898808B (zh) * | 2017-10-31 | 2021-04-27 | 华仁药业股份有限公司 | 小儿用静脉营养制剂 |
| RU2699222C1 (ru) * | 2019-04-29 | 2019-09-04 | Алексей Владимирович Воронов | Солевой электролитный раствор для проведения энтеральных инфузий |
| EP4125436A4 (en) * | 2020-04-01 | 2024-05-15 | The E. Wolfson Medical Center | ULCEROUS COLITIS DIET, RELATED FORMULAS, PRODUCTS AND METHODS |
| US20220378077A1 (en) * | 2021-05-25 | 2022-12-01 | Baxter International Inc. | Ready-To-Use Parenteral Nutrition Formulation |
| IT202200015885A1 (it) * | 2022-07-27 | 2024-01-27 | St G Gaslini | Sacca standardizzata per alimentazione di nati pretermine e dispositivo di alimentazione di nati pretermine |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3206784C2 (de) * | 1982-02-25 | 1985-05-09 | Pfrimmer & Co Pharmazeutische Werke Erlangen Gmbh, 8520 Erlangen | Glutaminhaltige Zubereitungen für orale oder intravenöse Applikation |
| FR2556594B1 (fr) * | 1983-12-20 | 1988-09-09 | Synthelabo | Solutions d'acides amines |
| US5684045A (en) * | 1985-09-12 | 1997-11-04 | Brigham And Women's Hospital | Method of treating pancreatic atrophy |
| JPH0710770A (ja) * | 1990-03-14 | 1995-01-13 | Otsuka Pharmaceut Factory Inc | アミノ酸輸液 |
| US5206220A (en) * | 1990-04-23 | 1993-04-27 | Research Corporation Technologies, Inc. | Soluble and stable sources of tyrosine, cysteine and glutamine for total parenteral nutrition |
| JPH05507472A (ja) * | 1990-04-23 | 1993-10-28 | リサーチ・コーポレイション・テクノロジーズ・インコーポレイテッド | 経静脈栄養法のためのチロシン、システイン、グルタミンの可溶性で安定な供給源 |
| SE9003844L (sv) * | 1990-12-03 | 1992-06-04 | Kabi Pharmacia Ab | Naeringstillsats |
| JPH06227974A (ja) * | 1993-01-29 | 1994-08-16 | Kyowa Hakko Kogyo Co Ltd | 栄養組成物 |
| US5438042B1 (en) * | 1993-10-08 | 1997-08-26 | Sandoz Nutrition Ltd | Enteral nutritional composition having amino acid profile |
| FR2711529B1 (fr) * | 1993-10-28 | 1996-07-05 | Clintec Nutrition Cy | Composition à base d'acides aminés destinée au traitement d'une infection ou d'une agression engendrant une réaction inflammatoire, chez les animaux et chez l'homme. |
| US5719133A (en) * | 1994-09-21 | 1998-02-17 | Novartis Nutrition Ag | Adolescent dietary composition |
| US5561111A (en) * | 1994-12-23 | 1996-10-01 | The University Of Virginia Patent Foundation | Stable glutamine derivatives for oral and intravenous rehydration and nutrition therapy |
| US6080788A (en) * | 1997-03-27 | 2000-06-27 | Sole; Michael J. | Composition for improvement of cellular nutrition and mitochondrial energetics |
| ID27818A (id) * | 1998-03-31 | 2001-04-26 | Nestle Sa | Metode untuk menyediakan glutamin |
| US7148199B2 (en) * | 2003-09-26 | 2006-12-12 | University Of Florida Research Foundation, Inc. | Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation |
-
2006
- 2006-04-20 DE DE102006018293A patent/DE102006018293A1/de not_active Ceased
-
2007
- 2007-03-05 WO PCT/EP2007/001878 patent/WO2007121807A1/de not_active Ceased
- 2007-03-05 AU AU2007241469A patent/AU2007241469B2/en not_active Ceased
- 2007-03-05 CA CA002647087A patent/CA2647087A1/en not_active Abandoned
- 2007-03-05 JP JP2009505732A patent/JP2009534323A/ja active Pending
- 2007-03-05 CN CNA2007800136921A patent/CN101420933A/zh active Pending
- 2007-03-05 CN CN201410705858.8A patent/CN104524542A/zh active Pending
- 2007-03-05 US US12/226,358 patent/US8377876B2/en not_active Expired - Fee Related
- 2007-03-05 MX MX2008013540A patent/MX2008013540A/es active IP Right Grant
- 2007-03-05 BR BRPI0710298-4A patent/BRPI0710298A2/pt not_active IP Right Cessation
- 2007-03-05 EA EA200870451A patent/EA015709B1/ru not_active IP Right Cessation
- 2007-03-05 KR KR1020087027628A patent/KR20090010050A/ko not_active Withdrawn
- 2007-03-05 EP EP07711788.5A patent/EP2007348B1/de not_active Not-in-force
- 2007-03-08 TW TW096108010A patent/TWI429405B/zh not_active IP Right Cessation
- 2007-04-20 AR ARP070101703A patent/AR060555A1/es unknown
-
2008
- 2008-09-12 ZA ZA200807860A patent/ZA200807860B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA015709B1 (ru) | 2011-10-31 |
| BRPI0710298A2 (pt) | 2011-08-09 |
| US20090203626A1 (en) | 2009-08-13 |
| EA200870451A1 (ru) | 2009-04-28 |
| AR060555A1 (es) | 2008-06-25 |
| WO2007121807A1 (de) | 2007-11-01 |
| JP2009534323A (ja) | 2009-09-24 |
| US8377876B2 (en) | 2013-02-19 |
| MX2008013540A (es) | 2008-10-31 |
| CN104524542A (zh) | 2015-04-22 |
| CN101420933A (zh) | 2009-04-29 |
| ZA200807860B (en) | 2009-08-26 |
| EP2007348B1 (de) | 2014-12-10 |
| KR20090010050A (ko) | 2009-01-28 |
| AU2007241469A1 (en) | 2007-11-01 |
| EP2007348A1 (de) | 2008-12-31 |
| CA2647087A1 (en) | 2007-11-01 |
| AU2007241469B2 (en) | 2012-09-20 |
| TW200740380A (en) | 2007-11-01 |
| DE102006018293A1 (de) | 2007-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI429405B (zh) | 用於靜脈營養療法的小兒胺基酸溶液 | |
| US8703725B2 (en) | Nutritional compositions | |
| AU669252B2 (en) | Medical foods for the nutritional support of child/adult metabolic diseases | |
| AU679020B2 (en) | Medical foods for the nutritional support of infant/toddler metabolic diseases | |
| EP1797891A1 (en) | Total enteral nutritious composition | |
| JPWO2008010472A1 (ja) | 総合経腸栄養組成物 | |
| EP0560989A1 (en) | Enteral preparation for cancer therapy | |
| JP3914585B2 (ja) | マクロファージ一酸化窒素産生亢進剤 | |
| RU2335927C2 (ru) | Обогащенные лейцином питательные композиции | |
| JPWO1988008259A1 (ja) | 栄養乳液製剤 | |
| ZA200501922B (en) | Leucine-enriched nutritional compositions. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |